William Blair Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at William Blair lifted their Q1 2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.24) per share for the quarter, up from their prior estimate of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.65) EPS and FY2026 earnings at $0.12 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday. Guggenheim upped their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Finally, Canaccord Genuity Group upped their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Buy” and an average target price of $22.14.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $8.31 on Friday. The stock has a market cap of $443.55 million, a P/E ratio of -4.22 and a beta of 1.98. The company’s 50-day simple moving average is $7.93 and its 200 day simple moving average is $8.15. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Insiders Place Their Bets

In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Several hedge funds have recently modified their holdings of the stock. Woodline Partners LP grew its stake in shares of Zevra Therapeutics by 2.2% during the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock valued at $34,524,000 after purchasing an additional 90,940 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Zevra Therapeutics by 462.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after purchasing an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock valued at $23,554,000 after purchasing an additional 68,151 shares during the last quarter. FMR LLC grew its stake in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. Finally, Altium Capital Management LLC grew its stake in shares of Zevra Therapeutics by 8.8% during the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock valued at $15,429,000 after purchasing an additional 150,000 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.